Nebivolol Desensitizes Myofilaments of a Hypertrophic Cardiomyopathy Mouse Model
Background: Hypertrophic cardiomyopathy (HCM) patients often present with diastolic dysfunction and a normal to supranormal systolic function. To counteract this hypercontractility, guideline therapies advocate treatment with beta-adrenoceptor and Ca2+ channel blockers. One well established pathomec...
Main Authors: | Sabrina Stücker, Nico Kresin, Lucie Carrier, Felix W. Friedrich |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2017-08-01
|
Series: | Frontiers in Physiology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fphys.2017.00558/full |
Similar Items
-
Familial hypertrophic cardiomyopathy: A case with a new mutation in the MYBPC3 gene
by: Olgu Hallioglu Kilinc, et al.
Published: (2017-07-01) -
An Update on MYBPC3 Gene Mutation in Hypertrophic Cardiomyopathy
by: Bogdan-Sorin Tudurachi, et al.
Published: (2023-06-01) -
Untargeted Metabolomics Identifies Potential Hypertrophic Cardiomyopathy Biomarkers in Carriers of <i>MYBPC3</i> Founder Variants
by: Mark Jansen, et al.
Published: (2023-02-01) -
A human <it>MYBPC3</it> mutation appearing about 10 centuries ago results in a hypertrophic cardiomyopathy with delayed onset, moderate evolution but with a risk of sudden death
by: Teirlinck Carolien H, et al.
Published: (2012-11-01) -
Heterogeneous Distribution of Genetic Mutations in Myosin Binding Protein-C Paralogs
by: Darshini A. Desai, et al.
Published: (2022-06-01)